-
Gene Editing Startup CRISPR Therapeutics Plots IPO
Boston Business Journal | The question remains whether CRISPR can do much better on the stock market than the other two publicly-traded gene editing companies, both of which are based in Cambridge and held IPOs earlier this year.
Sep 12, 2016
-
George Church May Be Called To Testify In CRISPR Fight
STAT | The University of California believes the visionary bioengineer will undermine key assertions made by the Broad Institute of Harvard and MIT.
Sep 8, 2016
-
Genentech To Get Multi-Million Tax Refund
San Mateo Daily Journal | Biotech company Genetech will receive a multi-million dollar refund on its tax bill, alleging it was assessed too much for machines and equipment; San Mateo County appeals decision.
Sep 8, 2016
-
Moderna Closes $474M Equity Financing
Bio-IT World Brief | Moderna Therapeutics announced today that it has raised $474 million. The company currently has $1.4 billion in cash on its balance sheet and the potential for over $230 million of additional available funds from grants.
Sep 7, 2016
-
First DNA Sequencing In Space A Success
Bio-IT World News | NASA has released a statement saying that the first DNA sequencing in space has occurred on the International Space Station.
Sep 7, 2016
-
Mylan Rebuffs Rumors CEO Will Step Down
BioSpace Mylan denies rumors that CEO will step down after controversy regarding EpiPen Auto-Injector.
Sep 6, 2016
-
tranSMART Foundation Launches Online Marketplace
Bio-IT World The tranSMART Foundation has launched a free marketplace of service vendors for the tranSMART platform. The marketplace was developed by tranSMART as a way to localize the vast world of data research and the vendors who offer services within that field.
Sep 2, 2016
-
Biogen’s Plaque-Busting Alzheimer’s Drug Shows Promise
MIT Technology Review | An antibody that clears up brain-destroying plaques may settle the cause of Alzheimer's once and for all.
Aug 31, 2016
-
How DNA Could Store All the World’s Data
Nature News & Comment | Modern archiving technology cannot keep up with the growing tsunami of bits. But nature may hold an answer to that problem already.
Aug 31, 2016
-
Novartis Dissolves CAR-T Unit Cutting 120 Positions
Forbes | Novartis is shutting down the business unit it created to develop white blood cells that can attack certain types of cancer, but continuing to develop such projects known as chimeric antigen receptor T-cells, or CAR-Ts.
Aug 31, 2016
-
Say hello to Dell Technologies on Sept. 7
Computerworld | Dell will complete its acquisition of EMC on Sept. 7, ending nearly a year of approvals and decades of history for the two companies that will combine to become Dell Technologies.
Aug 30, 2016
-
Excel Auto-Correct Creates Problems With Genomics Research
PCMAG | An Excel auto-correct feature changes gene names to dates. An Australian group dug through 7,500 Excel files published in 18 journals. About 20% of the files had errors.
Aug 30, 2016
-
tranSMART, IDBS, JAX and more: News from August 2016
Bio-IT World News Briefs | News, products, and partnerships from around the bio-IT community including news from tranSMART, JAX, Internet2, IDBS, Synthego, and more.
Aug 30, 2016
-
The Genetics of Type 2 Diabetes Is a Mess
Pacific Standard | A recent study shows why genetic advances in medicine are so challenging.
Aug 29, 2016
-
Digitizing The Pharma Research Value Chain For Faster Drug Discovery Through Precompetitive Collaboration
Bio-IT World Contributed Commentary | The global pharmaceutical industry is at a crossroads. It is, therefore, imperative for pharma organizations to reimagine their research value chain, in order to accelerate product innovation, and boost molecule pipelines during the discovery stage.
Aug 26, 2016
-
Stealthy Biotech Revives Stalled Parkinsons Drug Reveals Plans In Alzheimers and ALS
Forbes | Denali Therapeutics, the stealthy South San Francisco biotech startup that raised $217 million last year to fight Alzheimer's, Parkinson's and ALS, is finally lifting the curtain on its plans this morning.
Aug 25, 2016
-
Obama’s science legacy betting big on biomedical science
Nature News & Comment | Ambitious bids to map the brain and cure cancer have not boosted overall research funding.
Aug 22, 2016
-
With $14 Billion Purchase Pfizer Signals That Cancer Drug Prices Will Remain High
Forbes | Pfizer says it will purchase biotechnology upstart Medivation for $14 billion in cash. The main prize in the deal: Medivation's prostate cancer drug, Xtandi, which costs $120,000 a year.
Aug 22, 2016
-
Mass Innovation Labs Host Space for Growing Biotech
Bio-IT World “Something that the industry doesn’t really talk about is the cost of doing research,” says Amrit Chaudhuri, CEO of Mass Innovation Labs in Cambridge, Mass. Running a lab can cost hundreds of dollars per square foot, Chaudhuri says, but Mass Innovation Labs offers an alternative.
Aug 18, 2016
-
Lies damn lies and CRISPR the legal battle escalates
STAT | The gloves are off in the legal fight over CRISPR genome editing patents, as the latest documents filed in the case make clear.
Aug 18, 2016